L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006:(Scientific Opinion) by Sjödin, Anders Mikael
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
Published in:
E F S A Journal
DOI:
10.2903/j.efsa.2018.5137
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2018). L-carnitine and contribution to normal
lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006:
(Scientific Opinion). E F S A Journal, 16(1), [5137]. https://doi.org/10.2903/j.efsa.2018.5137
Download date: 03. Feb. 2020
SCIENTIFIC OPINION
ADOPTED: 13 December 2017
doi: 10.2903/j.efsa.2018.5137
L-carnitine and contribution to normal lipid metabolism:
evaluation of a health claim pursuant to Article 13(5) of
Regulation (EC) No 1924/2006
EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel),
Dominique Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait,
Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Monika Neuh€auser-Berthold, Gra_zyna Nowicka, Kristina Pentieva,
Yolanda Sanz, Anders Sj€odin, Martin Stern, Daniel Tome, Henk Van Loveren, Marco Vinceti,
Peter Willatts, Ambroise Martin, Sean (J.J.) Strain and Alfonso Siani
Abstract
Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientiﬁc substantiation of a health claim related to L-carnitine and normal lipid metabolism. The food
that is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine is
sufﬁciently characterised. The claimed effect proposed by the applicant is ‘normal lipid metabolism’.
The target population proposed by the applicant is the general population. The Panel considers that
contribution to normal lipid metabolism is a beneﬁcial physiological effect. The applicant proposes that
the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers
that the evidence provided does not establish that dietary L-carnitine is required to maintain normal
lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a
cause and effect relationship has not been established between the consumption of L-carnitine and
contribution to normal lipid metabolism in the target population.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the European
Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to
deliver an opinion on the scientiﬁc substantiation of a health claim related to L-carnitine and
contribution to normal lipid metabolism.
The scope of the application was proposed to fall under a health claim based on newly developed
scientiﬁc evidence.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications and the guidance on the
scientiﬁc requirements for health claims related to antioxidants, oxidative damage and cardiovascular
health.
The food proposed by the applicant as the subject of the health claim is L-carnitine. The
Panel considers that, the food/constituent, which is the subject of the health claim, L-carnitine, is
sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population
proposed by the applicant is the general population. The Panel considers that contribution to normal
lipid metabolism is a beneﬁcial physiological effect.
The applicant proposes that the claim submitted with this application is based on the essentiality of
a nutrient.
The Panel acknowledges that L-carnitine is needed for the transport of long-chain fatty acids across
the mitochondrial membrane, and therefore for their use as energy substrate. The Panel notes,
however, that the human body is able to synthesise L-carnitine from methionine and lysine, and that
there is consensus that L-carnitine is not an essential nutrient. No dietary reference values have been
set for L-carnitine.
The Panel notes that L-carnitine is considered an indispensable nutrient for (both preterm and
term) infants because of a temporarily insufﬁcient synthesising capacity, and that this is the reason
why a minimum L-carnitine content in infant formula has been established. The Panel also notes,
however, that this insufﬁcient capacity to synthesise carnitine cannot be extrapolated to any other
subgroup of the general healthy population, for which the claim is intended.
Carnitine deﬁciency understood as clinical symptoms which can be corrected by carnitine
administration has not been demonstrated in any other healthy population subgroup. In this context, the
references submitted by the applicant on carnitine transporter deﬁciency syndromes do not provide
evidence that dietary L-carnitine is required to maintain normal lipid metabolism in the target population
for the claim (general healthy population); no evidence was provided that dietary carnitine could reverse
the symptoms developed by the patient on long-term total parenteral nutrition and the supplementation
studies with L-carnitine in healthy subjects do not provide information on whether dietary carnitine is
required to maintain normal lipid metabolism (including normal fat oxidation), but rather on whether
supplemental carnitine could modify the rate of fat oxidation under certain conditions. Therefore, the
Panel considers that the evidence provided does not establish that dietary L-carnitine is required to
maintain normal lipid metabolism in the target population for which the claim is intended.
On the basis of data presented, the Panel concludes that a cause and effect relationship has not
been established between the consumption of L-carnitine and contribution to normal lipid metabolism
in the target population.
L-carnitine and contribution to lipid metabolism
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
in disease risk and to children’s development and health) which are based on newly developed
scientiﬁc evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: L-carnitine and contribution to
normal lipid metabolism.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of L-carnitine, a positive assessment of its safety, nor a decision on whether L-carnitine is, or
is not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is L-carnitine. L-carnitine
[(R)-(3-carboxy-2-hydroxypropyl) trimethylammonium hydroxide] is a zwitterionic quaternary
ammonium compound generally present in many foods in highly varying quantities. A trivial name is
levocarnitine. Only the L-isomer is biologically active. L-carnitine is present in biologic systems in both
non-esteriﬁed (free) and esteriﬁed forms bound to either long-chain fatty acids (acylcarnitine) or to an
acetyl group (acetylcarnitine). L-carnitine is essential for mammals to transport long-chain fatty acids
into the mitochondria.
Health relationship as claimed by the applicant
According to the applicant, the claimed effect relates to: ‘(normal) lipid metabolism. L-carnitine is
an endogenous substance in humans. It plays a fundamental biological role within lipid metabolism. Its
function is that of an essential carrier for long-chain fatty acids from the cytosol through the inner
mitochondrial membrane into the matrix, where beta-oxidation takes place. Therefore, L-carnitine is
needed for (normal) lipid metabolism. L-carnitine is a conditionally essential nutrient. The claimed
function in the human body is common knowledge. Therefore, outcome variables do not apply’.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
According to the applicant, L-carnitine is essential carrier for long-chain fatty acids across the
mitochondrial membrane.
Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘L-carnitine contributes to
normal lipid metabolism’. Equivalent alternatives are ’L-carnitine plays a role in lipid metabolism’ or
‘L-carnitine contributes to normal energy yielding metabolism’.
Speciﬁc conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is general
population. The proposed daily dose of L-carnitine provided as pure L-carnitine or the equivalent
amount of L-carnitine L-tartrate is 0.1–1 g per day via supplementation either in the form of food
supplements or fortiﬁed foods such as protein shakes/powder, beverages and bars.
Data provided by the applicant
Health claim application on consumption of L-carnitine and normal lipid metabolism pursuant to
Article 13.5 of Regulation 1924/2006, presented in a common and structured format as outlined in the
Scientiﬁc and technical guidance for the preparation and presentation of applications for authorisation
of health claims.2
As outlined in the General guidance for stakeholders on health claim applications,3 it is the
responsibility of the applicant to provide the totality of the available evidence.
The application does not include a request for data propriety and conﬁdentiality.
2.2. Methodologies
The general approach of the Dietetic Products, Nutrition and Allergies (NDA) Panel for the
evaluation of health claim applications is outlined in the EFSA general guidance for stakeholders on
health claim applications (EFSA NDA Panel, 2016).
The scientiﬁc requirements for health claims related to antioxidants, oxidative damage and
cardiovascular health are outlined in a speciﬁc EFSA guidance (EFSA NDA Panel, 2011a).
3. Assessment
3.1. Characterisation of the food/constituent
The food proposed by the applicant as the subject of the health claim is L-carnitine.
Carnitine is a quaternary ammonium salt synthesised primarily in the liver and kidneys from amino
acids, lysine and methionine. In living cells, carnitine is required for the transport of fatty acids from
the cytosol into the mitochondria for beta-oxidation. L-carnitine is the form commonly used in food
supplements. The content of L-carnitine in foods can be measured by established methods (EFSA NDA
Panel, 2011b).
The Panel considers that the food/constituent which is the subject of the health claim, L-carnitine,
is sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population
proposed by the applicant is the general population.
The Panel considers that contribution to normal lipid metabolism is a beneﬁcial physiological effect.
2 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Sj€odin A, Stern M, Tome D, Van Loveren H, Vinceti M, Willatts P, Martin A, Strain JJ, Heng L, Valtuena
Martınez S and Siani A, 2017. Scientiﬁc and technical guidance for the preparation and presentation of a health claim
application (Revision 2). EFSA Journal 2017;15(1):4680, 31 pp. https://doi.org/10.2903/j.efsa.2017.4680.
3 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. General scientiﬁc guidance for stakeholders
on health claim applications. EFSA Journal 2016;14(1):4367, 38 pp. https://doi.org/10.2903/j.efsa.2016.4367
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3.3. Scientiﬁc substantiation of the claimed effect
The EFSA NDA Panel has issued an opinion on a health claim related to L-carnitine and
maintenance of normal blood Low-density lipoprotein (LDL)-cholesterol concentrations pursuant to
Article 13(1) of Regulation (EC) No 1924/2006 with an unfavourable outcome (EFSA NDA Panel,
2011b). The unfavourable opinion was based on: a) the lack of a sustained effect of L-carnitine
consumption on blood cholesterol concentrations in humans; b) the impossibility to extrapolate the
effect observed in rats and rabbits to humans because of major differences in lipid metabolism
between species and c) the lack of evidence provided for a mechanism by which L-carnitine could
exert the claimed effect in humans. This claim was evaluated by the Panel as a claim NOT based on
the essentiality of nutrients.
The applicant proposes that the claim submitted with this application is based on the essentiality of
a nutrient. As stated in the general scientiﬁc guidance for stakeholders on health claim applications
(EFSA NDA Panel, 2016), the scientiﬁc substantiation of claims based on the essentiality of a nutrient
is determined by: i) the nutrient is required for normal human body function(s), i.e. it has an essential
mechanistic role in a metabolic function and/or it has the ability to reverse clinical signs and symptoms
of its deﬁciency; ii) the nutrient cannot be synthesised by the body or cannot be synthesised in
amounts which are adequate to maintain normal body function(s) and iii) the nutrient must be
obtained from a dietary source.
Pertinent publications were identiﬁed through a large collection of scientiﬁc publications compiled
by the applicant since 1986, permanently updated through a weekly search alert set in PubMed
including the key word carnitine, among others.
The Panel acknowledges that L-carnitine is needed for the transport of long-chain fatty acids across
the mitochondrial membrane, and therefore for their use as energy substrate. The Panel notes,
however, that the human body is able to synthesise L-carnitine from methionine and lysine, and that
there is consensus that L-carnitine is not an essential nutrient (IoM, 1989). No dietary reference values
have been set for L-carnitine.
The applicant claims that L-carnitine becomes conditionally indispensable under certain
circumstances, such as in some genetic disorders such as carnitine transporter deﬁciency syndromes
(Longo et al., 2006; Glenn and Gardner, 2007; Flanagan et al., 2010; Magoulas and El-Hattab, 2012),
that a case of carnitine deﬁciency after long-term total parenteral nutrition (TPN) has been reported in
the literature (Buchman et al., 1992) and that oral supplementation of L-carnitine increases fat
oxidation in healthy subjects (M€uller et al., 2002; Wutzke and Lorenz, 2004). The applicant also claims
that some abnormalities related to lipid metabolism (e.g. lower fatty acid concentration, higher
acetoacetate and b-hydroxybutyrate concentrations) were present in a group of infants receiving
carnitine-free parenteral nutrition shortly after birth (Christensen et al., 1989), and that L-carnitine is
mandatory in infant formula (Regulation (EU) No 609/2013).4
The Panel notes that L-carnitine is considered an indispensable nutrient for (both preterm and
term) infants because of a temporarily insufﬁcient synthesising capacity, and that this is the reason
why a minimum L-carnitine content in infant formula has been established (EFSA NDA Panel, 2014).
The Panel also notes, however, that this insufﬁcient capacity to synthesise carnitine cannot be
extrapolated to any other subgroup of the general healthy population, for which the claim is intended.
Carnitine deﬁciency, understood as clinical symptoms (rather than ‘low’ or ‘abnormal’ circulating
concentrations of carnitine, fatty acids or their metabolites) which can be corrected by carnitine
administration has not been demonstrated in any other healthy population subgroup (Rebouche,
1992). In this context, the references submitted by the applicant on carnitine transporter deﬁciency
syndromes do not provide evidence that dietary L-carnitine is required to maintain normal lipid
metabolism in the target population for the claim (general healthy population); no evidence was
provided that dietary carnitine could reverse the symptoms developed by the patient on long-term TPN
(Buchman et al., 1992); and the supplementation studies with L-carnitine in healthy subjects do not
provide information on whether dietary carnitine is required to maintain normal lipid metabolism
(including normal fat oxidation), but rather on whether supplemental carnitine could modify the rate of
4 Commission Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for
infants and young children, food for special medical purposes, and total diet replacement for weight control and repealing.
Council Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC
of the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009, Text with
EEA relevance. OJ L 181 29.6.2013 p. 35–56.
L-carnitine and contribution to lipid metabolism
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2018;16(1):5137
fat oxidation under certain conditions. Therefore, the Panel considers that the evidence provided does
not establish that dietary L-carnitine is required to maintain normal lipid metabolism in the target
population, for which the claim is intended.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of dietary L-carnitine and contribution to normal lipid metabolism in the target population.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, L-carnitine, is sufﬁciently characterised.
• The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target
population proposed by the applicant is ‘general population’. Contribution to normal lipid
metabolism is a beneﬁcial physiological effect.
• A cause and effect relationship has not been established between the consumption of
L-carnitine and contribution to normal lipid metabolism.
Steps taken by EFSA
Health claim application on ‘L-carnitine and normal lipid metabolism’ pursuant to Article 13(5) of
Regulation (EC) No 1924/2006 (Claim serial No: 0460_DE). Submitted by Lonza Ltd.,
M€unchensteinerstrasse 38, 4002 Basel, Switzerland. The scope of the application was proposed to fall
under a health claim based on newly developed scientiﬁc evidence.
1) This application was received by EFSA on 13/7/2017.
2) The scientiﬁc evaluation procedure started on 2/8/2017.
3) On 6/9/2017, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 22/9/2017 and was restarted on 6/10/2017, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
4) On 6/10/2017, EFSA received the applicant’s reply (which was made available to EFSA in
electronic format on 6/10/2017).
5) On 13/12/2017, the NDA Panel, having evaluated the data submitted, adopted by written
procedure an opinion on the scientiﬁc substantiation of a health claim related to L-carnitine
and normal lipid metabolism.
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